ICSDA: a multi-modal deep learning model to predict breast cancer recurrence and metastasis risk by integrating pathological, clinical and gene expression data. Issue 6 (14th October 2022)

• Record Type: Journal Article
• Authors: Yao, Yuhua; Lv, Yaping; Tong, Ling; Liang, Yuebin; Xi, Shuxue; Ji, Binbin; Zhang, Guanglu; Li, Ling; Tian, Geng; Tang, Min; Hu, Xiyue; Li, Shijun; Yang, Jialiang
• Is Part Of: Briefings in bioinformatics. Volume 23:Issue 6(2022)
• Publication Date: 2022-10-14
• Subjects: breast cancer -- recurrence and metastasis -- multi-modality -- residual network -- attention module; Genetics -- Data processing -- Periodicals; Molecular biology -- Data processing -- Periodicals; Genomes -- Data processing -- Periodicals; 572.80285
• DOI: 10.1093/bib/bbac448
• Languages: English
• ISSNs: 1467-5463

Abstract

Abstract: Breast cancer patients often have recurrence and metastasis after surgery. Predicting the risk of recurrence and metastasis for a breast cancer patient is essential for the development of precision treatment. In this study, we proposed a novel multi-modal deep learning prediction model by integrating hematoxylin & eosin (H&E)-stained histopathological images, clinical information and gene expression data. Specifically, we segmented tumor regions in H&E into image blocks (256 × 256 pixels) and encoded each image block into a 1D feature vector using a deep neural network. Then, the attention module scored each area of the H&E-stained images and combined image features with clinical and gene expression data to predict the risk of recurrence and metastasis for each patient. To test the model, we downloaded all 196 breast cancer samples from the Cancer Genome Atlas with clinical, gene expression and H&E information simultaneously available. The samples were then divided into the training and testing sets with a ratio of 7: 3, in which the distributions of the samples were kept between the two datasets by hierarchical sampling. The multi-modal model achieved an area-under-the-curve value of 0.75 on the testing set better than those based solely on H&E image, sequencing data and clinical data, respectively. This study might have clinical significance in identifying high-risk breast cancer patients, who may benefit from postoperative adjuvant treatment.